Healionics bags $1.7m in first financing round:
This article was originally published in Clinica
Healionics, a Redmond, Washington-based biomaterials start-up, has secured $1.7m in a series A financing round led by individual private investors. The funds will be used to scale up manufacturing of the firm's STAR (sphere templated angiogenic regenerative) material technology, expand and accelerate preclinical studies of the product and advance the company's business development activities. STAR is designed to enhance biocompatibility of medical devices intended for implantation in the body and to promote healing. Healionics has inked several agreements to apply the STAR material in diabetes, wound care and infusion therapy.
You may also be interested in...
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.
The FDA has almost 30 decision dates coming up before New Year’s Eve, including nearly a dozen novel agents.